Status:

RECRUITING

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Lead Sponsor:

Neuron23 Inc.

Collaborating Sponsors:

Qiagen Manchester Limited

Roche Diagnostic Ltd.

Conditions:

Parkinson Disease

Parkinson

Eligibility:

All Genders

40-80 years

Phase:

PHASE2

Brief Summary

The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the ...

Detailed Description

NEU-411-PD201 is a Phase 2, randomized, placebo-controlled, proof-of-concept study and open-label extension (OLE) in participants with early Parkinson's Disease (PD) who have LRRK2-driven PD as measur...

Eligibility Criteria

Inclusion Criteria:

  1. Aged 40-80 years at time of screening, inclusive
  2. Diagnosis of clinically established or clinically probable Parkinson's Disease (PD)
  3. LRRK2-driven PD using the investigational companion diagnostic genetic test (CDx)
  4. Modified Hoehn and Yahr (mH&Y) of 1 to 2.5

Exclusion Criteria:

  1. Secondary or atypical parkinsonian syndromes
  2. Uncontrolled diabetes mellitus with hemoglobin A1c (HbA1c) >8%
  3. Other significant medical conditions (as determined by medical history, examination, or clinical investigations at screening)

Additional inclusion and exclusion criteria for the RCP and OLE are outlined in the full study protocol.

Key Trial Info

Start Date :

January 17 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2027

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT06680830

Start Date

January 17 2025

End Date

September 1 2027

Last Update

April 13 2026

Active Locations (70)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 18 (70 locations)

1

Banner Sun Health Research Institute

Sun City, Arizona, United States, 85351

2

University of Arkansas

Little Rock, Arkansas, United States, 72205

3

Neuro-Pain Medical Center

Fresno, California, United States, 93710

4

University of California, Irvine

Irvine, California, United States, 92697

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease | DecenTrialz